News Avacta Group Plc

Stocks

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:21 12/06/2026 pm IST			5-day change	1st Jan Change
71.00 ^GBX	+3.65%		-0.70%	+22.41%

05/06	Avacta Group raises GBP9 million for bond repayments	AN
05/06	Avacta Therapeutics Raises GBP9 Million from Share Issue	MT

All News

Mentions Relevance

05/06	Avacta Group raises GBP9 million for bond repayments	AN
05/06	Avacta Therapeutics Raises GBP9 Million from Share Issue	MT
02/06	Avacta Therapeutics Presents Updated Clinical Data for Ava6000 in Salivary Gland Cancers At Asco 2026	CI
01/06	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026	GL
01/06	Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026	AQ
29/05	Avacta : Annual Report and Accounts for the year ending 31 December 2025	PU
29/05	Avacta Group plc Announces Board Changes	CI
29/05	Avacta Therapeutics Names Chairman Designate	MT
25/05	Avacta Group Plc - Special Call
22/05	Avacta Group Plc, 2025 Earnings Call, May 19, 2026
19/05	Avacta Group annual loss widens as cancer treatment trial results loom	AN
19/05	Avacta Therapeutics reports group revenues of £6.31 million for year ended December 31, 2025	RE
19/05	Avacta Group continues to explores multiple commercial opportunities with strategic partners	RE
19/05	Unaudited Preliminary Results for the Year Ended December 31, 2025	GL
19/05	Avacta Group Plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
06/05	Avacta : presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026	PU
06/05	Avacta presents new comparisons of pre\|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026	GL
06/05	Avacta Therapeutics Presents New Comparisons Of Pre\|CISION Payload Release Versus Approved ADCs And AVA6207 Dual Payload Delivery	CI
21/04	Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre\|CISION® delivery platform	GL
21/04	Avacta Therapeutics Presents Favorable Data for AVA6103 and Showcases Dual Payload pre\|CISION Platform At AACR 2026	CI
14/04	Avacta CEO Christina Coughlin Named as One of In Vivo's 2026 Rising Leaders	GL
09/04	Avacta hails "important milestones" in start of "transformative" year	AN
08/04	Avacta : Announces 2026 Science Day Event	PU
31/03	Avacta announces first patient treated in Phase 1 FOCUS-01 trial of FAP-Exd (AVA6103) - a sustained-release pre\|CISION® exatecan peptide drug conjugate	GL
31/03	Avacta Therapeutics Announces First Patient Treated In Phase 1 Focus-01 Trial Of FAP-Exd	CI